William Moss

William Moss is pediatric infectious disease specialist by training and a professor in the Departments of Epidemiology, International Health, and Molecular Microbiology at the Johns Hopkins Bloomberg School of Public Health. He received his medical degree from the Columbia University College of Physicians and Surgeons, his Master of Public Health degree from the Columbia University Mailman School of Public Health and completed his pediatric infectious disease fellowship at the Johns Hopkins School of Medicine. He is the Executive Director of the International Vaccine Access Center (IVAC) and a deputy director of the Johns Hopkins Malaria Research Institute at the Bloomberg School of Public Health.

His research interests are in measles, serological surveys, and malaria, as well as more broadly in vaccines and vaccine-preventable diseases. Professor Moss served on the SAGE Working Group for Measles and Rubella since its inception in 2011 until 2018, led the drafting of the Feasibility Assessment of Measles and Rubella Eradication that was presented to SAGE in October 2019 and later published in Vaccine, and co-authored the The Immunological Basis for Immunization Series Module 7: Measles in 2009 and 2019. He has been a member of IA2030 SP5 Working Group on Immunization in Fragile and Conflict-Affected Areas since January 2021. Professor Moss is program director of a malaria research project funded by the National Institutes of Health titled the “Southern and Central Africa International Centers of Excellence for Malaria Research” and has led a project funded by the Bill & Melinda Gates Foundation titled “Strengthening Immunization Systems through Serosurveillance”.